Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally thought to have high mortality rates. However, many cases can be treated with the right combination and rational use of available antituberculosis drugs. This Review describes the evidence available for each dr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet infectious diseases Jg. 10; H. 9; S. 621 - 629
Hauptverfasser:	Caminero, José A, Sotgiu, Giovanni, Zumla, Alimuddin, Migliori, Giovanni Battista
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Elsevier Ltd 01.09.2010 Lancet Publishing Group Elsevier Limited
Schlagworte:	Amikacin - therapeutic use Antitubercular Agents - classification Antitubercular Agents - standards Antitubercular Agents - therapeutic use Bacterial diseases Biological and medical sciences Capreomycin - therapeutic use Drug Resistance, Multiple Drugs Ethambutol - therapeutic use Extensively Drug-Resistant Tuberculosis - drug therapy Fluoroquinolones - therapeutic use Human bacterial diseases Humans Infectious Disease Infectious diseases Isoniazid - therapeutic use Kanamycin - therapeutic use Levofloxacin Medical sciences Ofloxacin - therapeutic use Pyrazinamide - therapeutic use Tuberculosis Tuberculosis - drug therapy Tuberculosis and atypical mycobacterial infections Infection Chemotherapy Treatment Tuberculosis Multiple resistance Bacteriosis Mycobacterial infection
ISSN:	1473-3099, 1474-4457, 1474-4457
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!